CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S129
DOI: 10.1055/s-0041-1727983
Abstracts
Head-Neck-Oncology: Medical Tumor Therapy

HANNA: Real-world outcomes of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (NIVO) in Germany

C-J Busch
1   Univ. HNO-Klinik, Greifswald
,
E von der Heyde
2   Onkologische Praxis am Raschplatz, Hannover
,
D Hahn
3   Klinikum der Landeshauptstadt Stuttgart, Stuttgart
,
C Langer
4   Universitätsklinikum Gießen und Marburg, Gießen
,
H Müller-Huesmann
5   Brüderkrankenhaus St. Josef, Paderborn
,
B Kubuschok
6   Universitätsklinikum Augsburg, Augsburg
,
D Beutner
7   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Universitätsmedizin Göttingen, Göttingen
,
G Klautke
8   Klinikum Chemnitz gGmbH, Chemnitz
,
P-S Mauz
9   Universitätsklinikum Tübingen, Klinik für Hals-, Nasen- und Ohrenheilkunde, Tübingen
,
J von der Grün
10   Universitätsklinikum Frankfurt, Klinik für Strahlentherapie, Frankfurt
,
J Büntzel
11   Südharz Klinikum Nordhausen gGmbH, Nordhausen
,
J Riera-Knorrenschild
12   Philipps-Universität Marburg, Marburg
,
B Tamaskovics
13   Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radioonkologie, Düsseldorf
,
M Welslau
14   Klinikum Aschaffenburg, Hämato-Onkologische Schwerpunktpraxis, Aschaffenburg
,
T Gauler
15   Universitätsklinikum Essen, Klinik für Strahlentherapie, Essen
,
D Waldenberger
16   Bristol-Myers Squibb GmbH&Co.KGaA, Medizinische Abteilung, München
,
A Dietz
17   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Leipzig
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction HANNA, a prospective, observational, multicenter study, started in May 2017 to collect data from patients (pts) with R/M SCCHN treated with NIVO in a real-world setting.

    Methods Overall, 56 clinics and practices plan to enroll 485 adult pts with R/M SCCHN starting therapy with NIVO according to the label. Pts are followed up to 5 years (y). The primary study objective is overall survival (OS), estimated using the Kaplan-Meier method. Data of 414 pts were analyzed in this interim analysis (Sept 2020, median follow-up 18.5 months [mo]) using descriptive statistics.

    Results Median age of pts was 63 y, 82.1 %  male, ECOG performance status 0-1/2-3 in 57.3 % /31.4 %  of pts, respectively. Primary tumor was oropharynx, 38.2 % ; hypopharynx, 18.6 % ; oral cavity, 22.5 % ; larynx, 14.5 % . 29.7 %  of pts received NIVO as first line therapy (1L) after platinum-based chemo- or radiochemotherapy, 50.5 %  as second line and 10.4 %  as later line therapy. Overall, 1y OS probability was 45 %  with a median OS (mOS) of 10.4 mo; pts receiving 1L NIVO had a 1y OS probability of 50 %  (mOS 11.9 mo). 1y OS probabilities/mOS were highest for pts with tumors of the hypopharynx (52 % , mOS 12.5 mo). Outcomes were more favorable for pts with local recurrence (56 % , mOS 15.3 mo) vs distant metastases (40 % , mOS 8.8 mo), and pts with soft tissue metastases (44 % , mOS 10.3 mo) vs bone metastases (24 % , mOS 4.7 mo). Comorbidities (eg. diabetes mellitus, coronary heart disease) had no influence on the outcome (50 % , mOS 11 mo/40 % , mOS 10.3 mo). Conclusions Real-world data from HANNA reflect routine clinical use of NIVO and provide complementary information about special populations. OS of our older, frailer patient population is comparable to outcomes from phase III NIVO registration study CheckMate 141.

    Poster-PDF A-1216.pdf

    Bristol Myers Squibb Deutschland


    #

    Conflict of interest

    The first author points out the following conflict of interest: Honorare und Reisekosten: BMS, Merck, MSD; Forschungsgelder: BMS

    Address for correspondence

    Dr. rer. nat. Waldenberger Daniela
    Bristol-Myers Squibb GmbH&Co.KGaA, Medizinische Abteilung
    München

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany